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Accurate assessment of blood haemostasis is essential for the management of patients who
use extracorporeal devices, receive anticoagulation therapy or experience coagulopathies.
However, current monitoring devices do not measure effects of haemodynamic forces that
contribute signiﬁcantly to platelet function and thrombus formation. Here we describe a
microﬂuidic device that mimics a network of stenosed arteriolar vessels, permitting
evaluation of blood clotting within small sample volumes under pathophysiological ﬂow.
By applying a clotting time analysis based on a phenomenological mathematical model
of thrombus formation, coagulation and platelet function can be accurately measured in vitro
in patient blood samples. When the device is integrated into an extracorporeal circuit in
pig endotoxemia or heparin therapy models, it produces real-time readouts of alterations
in coagulation ex vivo that are more reliable than standard clotting assays. Thus, this
disposable device may be useful for personalized diagnostics and for real-time surveillance of
antithrombotic therapy in clinic.
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R
apid, quantitative and accurate haemostasis monitoring is
critical in many clinical settings (for example, surgery,
trauma, sepsis, anticoagulation and anti-platelet therapies)
to anticipate, avoid and direct the management of serious
disorders due to bleeding or thrombosis1–3. An increasing
number of patients worldwide who are treated with the help of
extracorporeal assist devices (for example, haemodialysis,
membrane oxygenation, mechanical circulatory support, and
so on) require precise and personalized anticoagulation dose
monitoring on as close to real-time basis as possible to maintain
haemostasis in vivo, and to prevent clotting in the blood transport
lines and pumps of these devices ex vivo4,5. Most concerning is
that the inability to manage anticoagulation dosage precisely and
continuously is a common cause of catastrophic haemorrhage
and mortality in patients6. Moreover, the requirement for
monitoring haemostasis reliably at the bedside using low
blood volumes is even more critical in paediatric patients
with acute coagulopathy (acquired or congenital), as they are
more vulnerable than adults7–9.
Various tests and devices have been developed over many
decades to assess blood clotting and platelet function in vitro,
including assays for bleeding time, activated clotting time
(ACT), activated partial thromboplastin time (aPTT), thromboe-
lastography and platelet aggregometry. While these tests provide
useful information regarding coagulation status or platelet
function, they are limited in terms of their ability to predict
thrombotic or bleeding risk in clinical settings10–12 at least in
part because they fail to incorporate many of the key contributors
to haemostasis control that exist in vivo. For example, a
major limitation of these assays is that they measure clotting
behaviour under static (no ﬂow) or irrelevant ﬂow conditions,
and thus, they fail to incorporate the effects of haemodynamic
forces (pressure, ﬂow and shear stress) and related cellular
interactions that are known to signiﬁcantly impact whole
blood thrombosis in the living vasculature3,13. Notably, ﬂow
acceleration and deceleration (ﬂuid shear gradients) have been
shown to initiate platelet aggregation during arterial thrombosis
in vivo14,15, and clotting in extracorporeal devices usually
occurs at sites of sudden ﬂow disturbances, stagnation points
and stenosed sections of tubing16,17. However, none of the
routinely used haemostasis assays incorporate these physiological
conditions in their assessment of blood coagulation.
Microﬂuidic devices and parallel plate ﬂow chambers that
mimic atherosclerotic conﬁnement of vessels and reconstitute
physiological shear rates and gradients have been developed for
basic research studies using human whole blood in combination
with extracellular matrix (for example, collagen) surface
coatings15,18,19. These studies conﬁrmed that haemostasis
induced by blood contact with matrix varies depending on
local ﬂow conditions; however, the basic insights gained from
these studies have not been translated into clinical practice,
mainly because these devices are not designed for bedside use
or they require highly specialized instrumentation and imaging
systems19–23. Here we describe a simple microﬂuidic device for
real-time monitoring of haemostasis and platelet function
that permits rapid determination of a clotting time for native
whole blood as it is perfused through a network of channels, and
mimics local physiologically relevant changes in haemodynamic
ﬂow conditions experienced in living stenosed arterioles. A major
design advancement in this microﬂuidic device is that these
channels include multiple pre-stenosed and post-stenosed regions
in the ﬂow stream that generate both pathophysiological shear
rates and shear gradients, which act as haemodynamic activators
to cause blood clotting inside the device. To accurately assess clot
formation in an automated manner, changes in ﬂuid pressure
caused by increasing channel occlusion are tracked in real time in
the device, and a physiologically relevant ‘microﬂuidic’ clotting
time is derived as a quantitative end point using a novel
mathematical model. We demonstrate the sensitivity of this assay,
and the reliability of this microﬂuidic clotting time in vitro using
clinically relevant and patient samples. We also show that the
device can be integrated directly into vascular access lines and
blood-contacting medical devices for real-time ex vivomonitoring
of changes in haemostasis within native ﬂowing blood.
Results
Haemostasis monitoring microdevice. We designed a
microﬂuidic device containing microchannels that mimic
stenosed arterioles (for example, narrowed due to atherosclerotic
plaque formation) to create sudden ﬂuid acceleration (pre-
stenosis), followed by a region of uniform shear (stenosed region),
and then by a region with a sudden deceleration (post-stenosis),
when whole blood is perfused through the device (Fig. 1a). This
was achieved by allowing the blood to ﬁrst enter into a large
reservoir (B8mm wide, 75 mm high) and then splitting the ﬂow
into 12 smaller parallel channels (200 mm wide, 75 mm high);
followed by convergence of the ﬂow into an outlet similar to the
inlet (Fig. 1a). The 12-channel design was chosen to mimic a
vascular bed containing a network of multiple small vessels,
while simultaneously maximizing the surface area exposed to
ﬂowing blood to increase the likelihood of clot formation.
This design also produced a high dynamic measurement range
(B0.4–12 p.s.i.) and a good signal-to-noise ratio when a
commercially available pressure sensor was attached externally to
the device (Supplementary Fig. 1). In addition, the total width and
length of the device were designed to ﬁt on a standard glass
microscope slide to enable simultaneous real-time optical
microscopic imaging using a low magniﬁcation objective, while
ensuring near homogenous ﬂow in all parallel channels
(Fig. 1a,b). Each channel contained a few sections with alternating
60 bends and straight sections to achieve the highest possible
surface contact area available to promote clot formation, and
three replica devices were placed on each glass slide to permit
three parallel measurements (replicates) at the same time
(Fig. 1c). Finite element computational analysis of non-
Newtonian blood ﬂowing through the device conﬁrmed that for a
given ﬂow velocity inlet boundary condition, the wall shear rate
rapidly changes at the pre-stenosed and post-stenosed junctions
over a distance of B300mm, and remains mostly uniform in
the straight section (Fig. 1d, Supplementary Fig. 2). These
computational experiments also showed that a linear relationship
exists between the wall shear rate (g) at the straight section
(determined by the applied ﬂow rate) and the maximum shear
rate gradient ( _g) for this device design, due to ﬂow acceleration
and deceleration ð _g ﬃ 3:5gÞ (Fig. 1e). Based on this ﬁnding, we
calculated the difference in shear across the stenosed region in
our device, and determined that it corresponds to a shear change
equivalent to that produced when the diameter of an arteriole
decreases fromB 275 to 125 mm (j) orB55% stenosis, which is
typically seen clinically, for example, in patients with arterio-
sclerosis8,24. In practice, we operated the device so that the ﬂow
rates were maintained within the range of 5–150 ml min 1,
leading to wall shear gradients from B250 to 9,000 s 1mm 1,
which correspond to maximum wall shear rates from 75 to
2,500 s 1 (3–100 dynes cm 2) in the uniform region, which
again is typical for an arteriolar bed. Flow rates outside this range
also were undesirable as they would result in frequent red blood
cell sedimentation and require larger volumes of human donor
blood. In our experiments, when we added a low dose of heparin
anticoagulant (0.25 IUml 1) to native whole blood to prevent
immediate clotting before infusion into the device, and after
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perfusing the blood through microﬂuidic device forB20min, we
detected formation of various sized clots throughout its
entire length using ﬂuorescence imaging. However, much
more prominent and larger clots formed at the post-stenosed
region where the ﬂow suddenly decelerates (Fig. 1f) and we
could visualize trapped blood cells, ﬁbrin and elongated
platelets within the growing thrombus using electron
microscopy (Fig. 1g), conﬁrming that near-physiological
coagulation and platelet activation occur inside the device.
Importantly, this ﬁnding is reminiscent of thrombus formation
observed at stenosis sites in vivo, as well as inside extracorporeal
circuits in the clinic.
A mathematical formulation of clotting dynamics. The
dynamics of ﬁbrin clot formation in an arterial vessel in vivo, or
in an in vitro hollow channel, consist of three stages—a steady
reaction time, a growth phase and saturation (full stenosis)25.
To explore the dynamics of clot formation in our microﬂuidic
device, we performed time-lapse microscopic analysis of
whole human blood containing both a typical therapeutic
heparin dose (0.75 IUml 1; ref. 26) and ﬂuorescently labelled
ﬁbrinogen as it ﬂowed through the channel and entered a post-
stenosed region, at a pathologically relevant rate corresponding to
a wall shear gradient of 4,375 s 1mm 1 (Fig. 2a). When the
mean ﬂuorescence intensity, I(t), normalized by the intensity of a
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Figure 1 | The biomimetic haemostasis monitoring microdevice. (a) Diagram of the device with line drawings below showing the design of the
accelerating (pre-stenosed), uniform width (stenosed) and decelerating (post-stenosed) regions of the microchannels. The central stenosed region
contains 12 parallel lanes of 200-mm-wide and 75-mm-high channels that repeatedly turn 60 a few times in each channel (scale bar, 500mm).
(b) Schematic of the haemostasis monitor device and method. Human whole blood is pushed or pulled by a syringe through an inline pressure sensor that
connects to the device via tubing, and used to determine micro-clotting time. Optionally, ﬂuorescence microscopy of ﬁbrinogen and platelets allows
simultaneous monitoring of thrombus formation. (c) Photograph of three haemostasis monitoring devices formed in a single piece of PDMS mould on top
of a standard glass slide (75 50mm). (d) Graph showing results of computational modelling of blood ﬂow through the device. The wall shear rate
across the length of the entire device (pre-stenosed through stenosed and post-stenosed; from left to right) is shown for various inlet ﬂow velocities
(u¼0.01–0.5m s 1). (e) The computed wall shear gradients at the pre-stenosed (black circles) and post-stenosed (black squares) sections plotted
against the mean wall shear at the stenosed section (line of linear regression (dotted line); goodness of ﬁt, r2¼0.99; average slope, 3.49mm 1). This
linear relationship corresponds to a blood vessel that comprises ofB55% stenosis. (f) Representative ﬂuorescent micrographs of pre-stenosed, stenosed,
and post-stenosed regions of the same microﬂuidic device, showing ﬁbrin (top, green) and adhered platelets (bottom, red) after perfusing blood through
the device, containing heparin (0.25 IUml 1), for 20min (scale bar, 500mm). (g) Scanning electron micrographs of a blood clot formed inside the device
near the post-stenosed region shown at progressively higher magniﬁcations (left to right; scale bar, 500, 50, 10, 5 and 1 mm) demonstrating the presence of
ﬁbrin networks containing trapped blood cells (3 images at left), including activated platelets (2 right images).
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fully clotted region (Imax), was plotted against time, we found that
clotting followed a sigmoidal trend (Fig. 2a,b and Supplementary
Movie 1) involving sequential phases of steady reaction, growth
and saturation similar to those previously described25.
Based on this observation, we then used these sigmoidal
dynamics to derive a mathematical formulation of clot formation
(see Methods for details). The model led to the following relation
to predict pressure rise in a microchannel undergoing occlusion
when constant ﬂow is applied (Fig. 2c):
DP tð Þ
DP 0ð Þ¼ 1þ e
tTg
Ts Tg ð1Þ
Tg and Ts are the characteristic parameters of the ﬁtted
two-parameter exponential growth curve (reciprocal of sigmoid)
that represent time for the pressure to double and (1þ e) times its
initial value, respectively. For practical purposes, we derived a
clotting time that is the average of Tg and Ts, which we
determined to be equal to the time when the pressure rises to 2.86
times the initial pressure (Fig. 2c).
We then experimentally tested the model by investigating
clotting dynamics in ﬂowing native human whole blood
supplemented with different heparin concentrations when the
ﬂow rate was set to produce a shear gradient of 1,225 s 1mm 1.
The regression curve ﬁts based on the mathematical model
predicted the experimental data with a high accuracy (Fig. 2d,
goodness of ﬁts in Supplementary Table 1). To further determine
the robustness of the model, we varied the ﬂuid shear rate
gradients at a constant heparin concentration (0.5 IUml 1) and
analysed the pressure rise measured with the inline pressure
sensors; again, the regression curves accurately ﬁt the
experimental data (Fig. 2e, goodness of ﬁts in Supplementary
Table 1). Importantly, in all of the clotting time analyses done in
this study over the entire range of heparin concentrations and
shear gradients that we applied (Supplementary Table 1), we
found that the goodness of ﬁt (R2) was close to unity (0.89þ 0.11
s.e.m.), where R2¼ 0 indicates the model is theoretically fully
inaccurate and R2¼ 1 represents a theoretically perfect model.
Therefore, the microﬂuidic clotting time derived from
these curves can act as a highly reliable quantitative end
point for this clotting assay, including under conditions in which
blood contains therapeutically relevant heparin concentrations
(0–1 IUml 1), and under variable shear conditions that occur
within stenosed arterioles in vivo and that are the major sites of
thrombosis in various types of extracorporeal devices.
Microﬂuidic clotting time analysis. We next evaluated the
reliability of the microﬂuidic clotting times derived from these
regression models to determine if they can serve as quantitative
end points in lab and clinical settings. First, we measured heparin
sensitivity in the relevant concentration range (0–1 IUml 1),
and found that the clotting times accurately followed a linear
increase as the heparin concentration was raised from 0 to
1 IUml 1 at both low (1,225 s 1mm 1) and high (4,375 s 1
mm 1) ﬂuid shear gradient levels (Fig. 2f). This ﬁnding conﬁrms
that this device can be used to reliably monitor heparin therapy in
its clinical range within blood samples in vitro.
Because current haemostasis tests used in the clinic do not
incorporate the physiological contributions of haemodynamic
shear stresses and gradients27, we explored whether we can detect
changes in clotting times in response to pathophysiological
variations in shear rates and gradients in our microdevice.
Arterial clotting is dominated by platelet activation and
aggregation that increase with shear27,28. Here, we observed an
exponential decrease in microﬂuidic clotting time as the shear
rate gradient increased from 525 to 8,750 s 1mm 1 at heparin
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Figure 2 | Mathematical formulation and empirical validation of clotting
time. (a) Representative ﬂuorescent micrographs of ﬁbrin (green) deposited
within the microchannel after blood containing heparin (0.75 IUml 1) was
perfused through the channel for 0, 25, 50 and 60min at a shear rate
gradient of 4,375 s 1 mm 1 (scale bar, 250mm). (b) The ﬂuorescence
intensity of ﬁbrin clot normalized by the maximum (black circles), showing a
sigmoidal trend (dotted line, goodness of ﬁt, R2¼0.99; n¼ 3 donors, 1
replicate per experiment) over time in the observed region. Due to sigmoidal
thrombus growth, the pressure rise across the device (relative to the
pressure at the initial time) will follow a two-parameter (Tg and Ts)
exponential (reciprocal of sigmoid) trend. (c) A representative plot showing
mathematical function to predict thrombus formation with Tg¼ 30min and
Ts¼45min. Microﬂuidic clotting time (mCT) is average of Tg and Ts. (d,e)
Representative graph showing empirical validation of the analytical model by
varying heparin (d; 0, 0.1, 0.5 and 1 IUml 1; labelled in different shades of
grey) at a given shear rate gradient of 1,225 s 1mm 1, and by varying shear
rate gradient (e; 525;1,225;2,625 and 5,250 s 1mm 1; labelled in different
shades of grey) at heparin concentration of 0.5 IUml 1. (goodness of ﬁts for
d and e are presented in Supplementary Table 1; three experiments were
performed for every condition). (f,g) Graph showing empirical validation of
mCT derived from the phenomenological analytical model, by varying the
heparin concentration in the range of 0–1 IUml 1 and perfusing blood at
shear rate gradients of 1,225 s 1mm 1 (black circles) and 4,375 s 1 mm 1,
(grey circles) respectively (f; line of linear regression (dotted line);
goodness of ﬁt, R2¼0.99 and 0.98, respectively; n¼ 3 donors, 1 replicate
per experiment); and by varying the shear gradient in the range
262–8,750 s 1mm 1 and perfusing blood at heparin concentrations of
0.25 IUml 1 (black circles) and 0.5 IUml 1 (grey circles), respectively
(g; exponential decay regression curve (dotted line); goodness of ﬁt,
R2¼0.76 and 0.79, respectively; n¼ 3 donors, 1 replicate per experiment).
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concentrations of 0.25 and 0.5 IUml 1 (Fig. 2g), conﬁrming that
this microﬂuidic clotting time analysis is also sensitive to changes
in platelet function due to variable ﬂuid shear.
A rapid in vitro platelet function test under stenosed ﬂow. As
platelet aggregation is a major contributor to the development of
vascular occlusion,29 we further explored if this biomimetic
device can be used as a rapid platelet function assay under
stenosed ﬂow. First, to reduce the blood volume and time
required for analysis, we functionalized the surface of the
microchannel within the device with collagen, which is a
commonly applied platelet agonist.20 This reduced the
microﬂuidic clotting time signiﬁcantly (Po0.05; multiple
t-tests), thereby enabling us to use the device to perform
clotting analysis in a few minutes using o1ml of human whole
blood (Fig. 3a). Notably, even after collagen coating, we still
observed larger amounts of ﬁbrin and platelet aggregates in the
post-stenosed regions, which is consistent with past ﬁndings
suggesting that the shear rate gradient in the decelerating ﬂow
region may be a major contributor to the haemostatic
response14,15 (Fig. 3b). Next, we used the collagen-coated
devices to analyse blood samples that were anticoagulated with
sodium citrate, which were then reconstituted with calcium and
magnesium immediately before infusion into the device to
reactivate the coagulation cascade. When the anti-platelet drug
abciximab (Reopro) that targets integrin aIIbb3 was added at
clinically relevant increasing doses (0, 5 and 20 mgml 1) to blood
samples drawn from healthy individuals, we observed a dose-
dependent rise in microﬂuidic clotting time (Po0.05; one-way
analysis of variance (ANOVA); Fig. 3c). When we perfused blood
from patients who were treated chronically with the dual anti-
platelet regimen of aspirin (cyclooxygenase inhibitor) and
clopidogrel (Plavix; P2Y12 inhibitor), we also detected a
signiﬁcant increase in clotting time relative to healthy
individuals (Po0.05; unpaired t-test; Fig. 3d).
We then explored whether we could use this collagen-coated
device to measure clotting defects in blood samples from patients
with Hermansky–Pudlak syndrome (HPS), which is an extremely
rare bleeding disorder characterized by a deﬁciency of platelet
dense granules. Importantly, conventional standard platelet
aggregation assays (PFA-100, bleeding time etc.) commonly do
not detect the platelet defect in HPS patients, and neither these
methods nor platelet aggregometry are recommended as a ﬁrst
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Figure 3 | Rapid platelet function analysis in vitro (a) Microﬂuidic clotting time (mCT) measured when the blood is perfused (shear rate
gradient¼ 1,225 s 1 mm 1) through a haemostasis monitoring microdevice coated with collagen (black bars, 100mgml 1) compared with bare surface
(white bars), shown at two different heparin concentrations (0.25 IUml 1 and 0.5 IUml 1, respectively; *Po0.05, multiple t-tests, s.e.m.; n¼ 3 donors, 2
replicates per experiment). (b) Representative ﬂuorescent micrographs of pre-stenosed, stenosed and post-stenosed regions of the same collagen-coated
microﬂuidic device (shear gradient, 4,375 s 1 mm 1), showing ﬁbrin (top, green) and adhered platelets (bottom, red) after it occluded due to perfusion of
recalciﬁed citrated blood for 20min (scale bar, 500mm). (c) mCTmeasured for citrated blood containing different doses of an anti-platelet drug, abciximab
(Reopro), when perfused through the device after recalciﬁcation (shear gradient, 4,375 s 1 mm 1; *Po0.05, one-way ANOVA, s.e.m.; n¼ 3 donors, 2
replicates per experiment). (d) mCTmeasured from perfused recalciﬁed citrated blood samples (shear gradient, 4,375 s 1 mm 1) of healthy donors (white
bars) versus patients who take Aspirin and Plavix (clopidogrel) regularly (black bars) (*Po0.05, unpaired t-test, s.e.m.; n¼ 5 healthy donors and 9 patients,
2 replicates per experiment). (e) A representative trace of pressure rise measured in the device, and ﬂuorescent micrograph showing ﬁbrin (top left,green)
and platelet (top right,red) deposition at the post-stenosed region of the device, when blood from a healthy individual (H) was ﬂowed through the device
compared with blood from an HPS patient (P; shear gradient: 4,375 s 1 mm 1; scale bar: 500mm). HPS, Hermansky–Pudlak Syndrome.
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line clinical test for this syndrome; as a result, time consuming
and specialized electron microscopy is still required for an
unequivocal diagnosis at this time30. Interestingly, when we
perfused the device with blood from two HPS patients, we did not
observe any clotting for the entire duration of the experiment in
either subject, and their blood did not clot even when we applied
a wall shear rate gradient as high as 8,750 s 1mm 1 (Fig. 3e and
Table 1). These ﬁndings show that the shear gradient-activated
microﬂuidics device is highly sensitive in detecting platelet defects
in these HPS subjects, and that the clinical manifestation of this
disease (that is, failure to form clots normally within ﬂowing
blood in vivo) can be effectively recapitulated in vitro using this
new method. This observation also inspired us to explore if
occlusion in this device is dependent on the release of ADP
agonist31,32 from platelet dense granules, which are dysfunctional
in HPS patients. To test this, we added ADP to the blood of HPS
patients and found that adding ADP reversed their clotting defect
in the microﬂuidic device (Table 1), further conﬁrming sensitivity
to defective ADP release and providing another independent
biomarker to evaluate bleeding in HPS patients.
Together, these proof-of-concept studies demonstrate that
clotting time analysis in the microﬂuidic device is sensitive to
platelet adhesion to collagen and modulation of platelet activation
pathways that are most commonly targeted by current anti-platelet
regiments, including the ADP-P2Y12 pathway, the cyclooxygenase
pathway, and activation through aIIbb3. By studying a small
number of HPS patients, we also demonstrated that this device can
be used to detect this extremely rare condition, which cannot be
easily detected by conventional platelet aggregation or blood
clotting assays. Thus, this microﬂuidic haemostasis monitoring
device potentially offers a convenient new method for global
assessment of platelet function, monitoring anti-platelet therapies,
and evaluating human patients with bleeding disorders.
Ex vivo monitoring of coagulopathy and heparin therapy.
Another major unmet need in the haemostasis ﬁeld is the ability
to measure the coagulation status of patients in real time within
blood ﬂowing through extracorporeal circuits. Under these con-
ditions, patients commonly require frequent haemostasis mon-
itoring to ensure therapeutic anticoagulation is maintained at
effective levels, and to rapidly detect any life-threatening
thrombotic or bleeding events that might arise. To explore the
potential utility of using this microﬂuidic device as an ex vivo
haemostasis monitor, we integrated a three-channel device
directly into a vascular access line that was inserted into the
femoral vein of a living pig (Fig. 4a) and performed two separate
proof-of-concept studies. Animal models of endotoxemia induced
by intravenous infusion of lipopolysaccharide (LPS) are widely
used to study disruption of haemostasis and intravascular coa-
gulation owing to sepsis33 Therefore, we ﬁrst injected a lethal
dose of LPS intravenously to the pig for 90min and then
monitored the coagulation state of the animal’s blood for 6 h.
Samples were drawn from the venous access line for conventional
blood analysis (complete blood count, blood chemistry and
coagulation parameters) and the clotting time was also
determined by ﬂowing blood from the access line directly
through an integrated microﬂuidic device, which was replaced
with a new device every hour over the period of study.
LPS infusion resulted in signiﬁcant changes in blood cell
parameters and haemostasis relative to baseline, including decrease
in white blood cell count within 2 h, followed by a rapid increase in
white blood cell numbers, as well as an increase in neutrophils, rise
in haematocrit, and decrease in platelet counts over 6 h
(Supplementary Fig. 3). In addition, activation of the coagulation
cascade occurred, as indicated by signiﬁcant increases in plasma
thrombin-antithrombin (TAT) complexes and42-fold increase in
plasma ﬁbrinogen levels over baseline (Po0.05; one-way ANOVA)
(Fig. 4b,c). Importantly, we also were able to rapidly detect
development of this prothrombotic state using the microﬂuidic
device coupled to the vascular access line, as evidenced by a
signiﬁcant decrease in microﬂuidic clotting time (Po0.05; one-way
ANOVA; Fig. 4d). Moreover, the trend of our clotting end point
over time correlated more closely with these speciﬁc plasma
biomarkers, when compared with the standard ACT and aPTT
coagulation assays, as determined by the Pearson correlation
coefﬁcient, r (Fig. 4e and Supplementary Fig. 4). In fact, the aPTT
resulted in a positive r, which indicates that it was highly
insensitive to the elevated biomarkers. Moreover, it yielded a trend
in clotting time opposite to what would be expected, and thus, it
was the worst among the three assays we tested.
In a second study, we injected single doses of different
concentrations of unfractionated heparin intravenously into a
pig, and determined clotting times sequentially ex vivo using a
collagen-coated microﬂuidic device within 10min after each dose,
while also measuring ACT, aPTT clotting times and plasma
heparin concentrations in blood samples drawn in parallel. We
found that plasma heparin concentration rose linearly in response
to increasing heparin doses over the clinical therapeutic range
applicable to humans (Fig. 4f)26. Heparin dose-dependent
increases in aPTT and ACT times were also detected as expected
(Supplementary Fig. 5); however, the aPTT test was only sensitive
in the lower heparin range and it could not measure effects of
heparin when used at doses B100 IUkg 1 (Supplementary
Fig. 5). Importantly, in addition to displaying a linear dose
response, the microﬂuidic clotting times we determined ex vivo
using the microﬂuidic device were also signiﬁcantly more sensitive
than those measured using aPTT and ACT tests (sensitivity for all
tests was deﬁned as the slope of the linear ﬁt of test value versus
heparin dose; Po0.01; one-way ANOVA; Fig. 4g,h).
These studies show that the haemostasis assessment micro-
device can be successfully integrated into the blood lines of
extracorporeal circuits and used ex vivo to monitor developing
coagulopathy and anticoagulation therapy directly in living
patients, which could have great value for children as well as
adults. Moreover, this device applied ex vivo appears to be more
reliable than standard aPTT and ACT laboratory assays, and
importantly, it eliminates the need to use anticoagulant collection
tubes which further minimizes the chance of pre-analytical errors
that complicate existing clinical assays34.
Discussion
The biomimetic haemostasis monitoring device described here
provides several potential advantages over other analytical devices
and ﬂow chambers that quantitate high-shear thrombosis,
although it also has some limitations. First, due to the presence
of whole blood ﬂow and stenosed shear gradients in the device,
clot formation occurs under near-physiological conditions and
Table 1 | Clotting time analysis of patients with Hermansky–
Pudlak Syndrome (HPS).
Shear gradient
(s 1 mm 1)
4,375 8,750 4,375 4,375 4,375 4,375
ADP (mM) 0 0 1 5 7.5 10
mClotting Time
(min; Patient 1)
N N N N 9.45 6.23
mClotting Time
(min; Patient 2)
N N N N 7.67 4.56
Mean of three replicates per experiment. N: blood did not clot in the device.
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includes complex blood rheology that is critical to thrombosis.
The device was microfabricated to create a ﬁxed 55% stenosed
lesion in each channel that cannot change during the course of
the study, as might occur in vivo; however, the user can still apply
shear rate gradients to mimic patient-speciﬁc medical conditions.
For example, analysis of blood from atherosclerotic patients
who have a higher degree of in vivo stenosis documented
clinically (for example, by imaging) might be carried out using
higher shear gradients that better correspond to the severity of the
condition.
Another major advantage of this screening device is that real-
time evolution of blood clots can be recorded and quantiﬁed
easily using just a blood pump, a disposable pressure sensor and a
display monitor (imaging equipment is optional), all of which are
also part of most extracorporeal circuits and hence, currently used
widely in medical settings35,36. In fact, the blood can be pumped
in two operating modes—constant ﬂow rate—where exponential
growth of pressure is recorded, or alternatively, constant pressure
where sigmoidal decay in ﬂow is measured. Blood could be drawn
from the high-pressure arterial line directly into the device, thus
further eliminating the need of a blood pump. The feasibility of
this approach has been demonstrated by using this device with a
constant pressure pump to measure sigmoidal changes in ﬂow
across a microchannel as a way to evaluate an antithrombotic
surface coating that could potentially be used in extracorporeal
circuits37.
Using this device, we also were able to identify a microﬂuidic
clotting time that serves as an automated, robust and physiolo-
gically relevant analytical end point of this assay by applying a
highly predictive phenomenological mathematical model to the
biomimetic occlusion measurements. This derived clotting time
has a high dynamic range to monitor heparin therapy in vitro,
and it shows an exponential decay to increasing shear gradients
mapping the sensitivity to platelet thrombi formation under ﬂow,
making this device well suited to explore whether novel anti-
coagulants and anti-platelet drug candidates produce different
behaviours in clotting dynamics. Importantly, using this model-
based approach, we required o3-fold rise in pressure drop to
reliably measure haemostasis, which minimizes the time and
blood volumes that are required to carry out these studies.
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Figure 4 | Ex vivo monitoring of coagulopathy and anticoagulation therapy in pigs. (a) Photograph showing a functioning microﬂuidic device attached to
the femoral vein of a pig via a trilumen catheter. Blood is pulled at a set ﬂow rate (shear gradient¼4,375 s 1 mm 1) so that it passes through the device
and the inline pressure sensor, forming clots inside the device; pressure data are automatically acquired on a laptop. (b–d) endotoxemic shock model.
Lipopolysaccharide endotoxin (LPS) was infused into a pig over 1.5 h (grey shaded region,  1.5–0 h), and then thrombin-antithrombin (TAT) complexes in
plasma (b; baseline¼ 11.95 ngml 1), ﬁbrinogen concentration in plasma (c; baseline¼ 143.61 ngml 1), and microﬂuidic clotting time (mCT) calculated
using the microchip (d; baseline¼ 20.64min; *Po0.05 compared with baseline, one-way ANOVA, s.e.m.) were measured every hour thereafter.
(e) Pearson correlation coefﬁcient (r) of aPTT (light grey), ACT (dark grey) and mCT (green) compared with TATand ﬁbrinogen measurements (n¼ 3 pigs,
2 replicates per experiment). (f,g) Heparin therapy model. Fold change (relative to baseline at no heparin), in heparin concentration (black circles)
measured by Factor Xa assay (f) and mCT (black circles) measured using the microﬂuidic haemostasis monitor (g) (baseline¼4.25min; full line, line of
linear regression; dotted line, 95% conﬁdence interval of the linear ﬁt). (h) Graph showing the sensitivity of aPTT (light grey), ACT (dark grey) and mCT
(green) assays (**Po0.01, one-way ANOVA, s.e.m.; n¼ 3 pigs, 2 replicates per experiment).
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Another unique feature of our device is the incorporation of
multiple parallel stenosed channels. We chose this design to
better mimic clotting within a natural blood vessel network than
using one very long channel, which would more closely resemble
a single occluded vessel. This design is analogous to clotting
within multiple vessels of a vascular network (that is, instead of a
single vessel) that occurs in living patients with coagulopathies
in vivo where clots may form, deform, translocate and detach
locally, but the pressure still increases in the vascular bed due to
the systemic response to thrombosis. Use of multiple parallel
channels, combined with our mathematical model that acts as a
digital ﬁlter, also allows the device to overcome the granularity of
responses that can occur in single channels (for example, due to
occasional passing of debris, air bubbles or other local perturba-
tions), and provide a more robust global measurement of system-
level coagulation behaviour and platelet function. In addition, this
design allowed us to maximize the number of stenosed regions
and the total surface contact area available to promote blood clot
formation. We were also able to ﬁt multiple replicas of the entire
device on a microscope slide in this initial characterization study
so that we could visualize thrombus formation and validate the
results obtained with our pressure measurements. Finally, the
12-channel design generated a dynamic range of pressures that
were easily measured using our commercially available pressure
sensor. However, we have not optimized the parallel network
design, and with different design constraints it is possible that
other channel designs, or even use of single channels, could be
feasible. Thus, further design optimization will need to be carried
out if this technology is advanced towards clinical applications.
This device also had limitations, however. For example, the
time to assess clotting is not instantaneous and it does not permit
continuous monitoring of clotting in ﬂow loops as each device
would need to be discarded after every sequential measurement.
But most existing haemostasis assays are also not instantaneous,
and clinical decisions are often made over the time span of many
hours. Thus, the 10–20min that are required for completion of
this assay by the bedside using disposable analytical components
that can be snapped in and out over time should still be valuable
for clinical analysis.
One of the major features of our device is that it also can
effectively monitor platelet function in whole blood, which can be
applied to analyse bleeding risk in patients who are not easily
diagnosed. Interestingly, being a global and quantitative haemos-
tasis test, this device offers a potential way to analyse more
complex coagulopathies, such as sepsis and sickle cell anaemia,
where other cells (for example, bacteria and sickled erythrocytes,
respectively) also contribute to alterations in haemostasis. More-
over, because this device can be functionally integrated with
extracorporeal circuits and indwelling medical devices as we
showed here, it could provide a relatively simple and more
reliable way to monitor coagulopathies and effects of antithrom-
botic therapy over time using native blood in both critical care or
home care settings.
Finally, we have also gained some interesting new insights into
the biophysical process of thrombus formation through use of
this device. For example, while increased coagulation has been
observed in regions of living vessels that experience high-shear
rates25 and shear rate gradients14 in the past, it was not possible
to determine which of these parameters is the most critical trigger
for coagulation. In contrast, our ability to independently vary
shear rate gradients using our microﬂuidic device design allowed
us to show that the shear gradient in the post-stenosed
(decelerating ﬂow) region is the more critical activator of
coagulation, and that the overall microﬂuidic clotting time
shortens exponentially as the applied shear rate gradient
increases. The cause of this response is unknown, but it is likely
due to the activation of clotting factors, platelets and/or immune
cells via ﬂuid dynamics-dependent mechanical signalling
pathways that remain to be deﬁned. In any case, these ﬁndings
suggest that this microﬂuidic device may be useful for
mechanistic studies, in addition to serving as a potential clinical
diagnostic device.
Methods
Microdevice fabrication. The devices were designed to ﬁt on a standard
(75 50mm) microscope slide to simplify microscopic analysis using the Auto-
CAD software and we used SU8 2075 (MicroChem. Corp.) master templates
fabricated on Si (100) wafers (University Wafer Corp.) using photolithography.
The devices were fabricated using soft lithography of PDMS38. Slygard 184 PDMS
prepolymer (Dow Corning) was cast on the silanized master which had the positive
relief of the channel features formed by the SU8 photoresist. The PDMS was then
cured at 60 C in a convection oven for 3–4 h. The cured PDMS was peeled off the
master and bonded to a 500-mm-thick PDMS-coated glass slide after treating both
with oxygen plasma (100W, 30 s) and punched with a 4mm hole at the inlets and
outlets (Harris Uni-Core, VWR).
Principle of coagulation monitoring. Fresh human blood stored in a 5ml syringe
(BD) or a ﬂuid reservoir is pushed or pulled via syringe pump (PHD Ultra CP,
Harvard Apparatus) through an inline, disposable pressure sensor (PendoTECH)
followed by the PDMS device, respectively. The channel occlusion is measured by
recording the rise in pressure over time (5 kPa or above) using data acquisition and
analysis software (Winwedge Pro, TALtech). Polyvinyl chloride tubing connected
to female luer lock and male luer slip ﬁttings on either ends, respectively, (Qosina
Corp, Edgewood, NY) is directly bonded (luer slip end) to the inlet and outlet ports
of the device, respectively. The latter end of the inlet side tubing is connected to the
pressure sensor and the outlet side of the tubing is dipped in 3.2% sodium citrate
(Fig. 1a,b). To signiﬁcantly reduce clot formation inside the syringe, sensor and
tubing, we treated the blood-contacting surfaces with a bioinspired surface coating
described elsewhere37. When the blood was ﬁlled in a syringe and pushed, the
syringe was manually agitated every 2–3min to prevent sedimentation of
erythrocytes in the blood. In studies where heparin blood was used, different shear
rates and gradients were applied to determine the validity of the clotting time
analysis and analyse the response to shear changes. Recalciﬁed citrated blood from
patient samples were used for platelet function analysis. All studies were performed
at a shear rate gradient of 4,375 s 1mm 1 to cause rapid clotting within a few
minutes and to limit the patient blood volume required to o0.5ml. Thrombus
formation was observed using time-lapse imaging ( 10, numerical aperature 0.3;
Zeiss Axio 3 Observer) of ﬂuorescently labelled ﬁbrinogen (150mgml 1, Alexa
Fluor 488, Invitrogen) and platelets. Human CD41-PE antibody (10 ml ml 1,
Invitrogen) was added directly to the blood and incubated at room temperature for
10min for platelet imaging. Standard wide-ﬁeld ﬂuorescence micrographs of ﬁbrin
and platelet staining were recorded to demonstrate total thrombus volume in the
different regions of the device; multiple ﬂuorescent microscopic images recorded
from neighbouring regions using automatic scanning were also stitched together to
form large region panoramas. For data recording and analysis, the initial time
(t¼ 0) was the time when the blood entered the device. The heparin concentration
and ﬂow rate were varied independently in these experiments. The wall shear
stress/rate corresponding to the imposed ﬂow rate at the uniform width region was
determined from analytical formulae derived for rectangular microchannels24 and
shear gradients at the pre-stenosed and post-stenosed regions were predicted from
computational analysis.
Computational analysis of shear rate gradients. Finite element-based software,
COMSOL Multiphysics v5 (COMSOL Inc, Burlington, MA) was used to simulate
blood ﬂow inside the microdevice. The AutoCAD line drawing of the entire
device in .dxe format was exported to COMSOL. Blood was assumed to be a
two-dimensional incompressible ﬂuid, homogenous and non-Newtonian. A
high-density ﬁnite element mesh was constructed for precise calculations. The
Navier–Stokes equation of ﬂuid dynamics was solved by assigning a ﬁnite velocity
as the inlet boundary condition, and constant atmospheric pressure (P¼ 0) at the
outlet boundary. To describe the stress-strain relationship and blood viscosity, a
generalized power-law constitutive equation for non-Newtonian ﬂuids was applied
and parameters were chosen based on published values39,40. COMSOL was able to
calculate and export the values of wall shear rates along the selected boundary
edges during post processing. Shear gradients were calculated by computing the
slope of the shear rate near the pre-stenosed and post-stenosed regions.
Mathematical formulation of clotting dynamics. We developed a mathematical
formulation of clot formation dynamics based on the sigmoidal dynamics of
thrombus formation observed on blood perfusion inside the device (Fig. 2b). Based
on the previous studies showing that the size of a growing thrombus measured
in vitro correlates linearly with measured light intensity41,42, we can approximate
that I tð ÞImax  1
A tð Þ
Amax
¼ SigðtÞ, where A(t) is the cross-sectional area available for
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blood ﬂow through the occluding channel at a given time, Amax is the initial cross-
sectional area of the microchannel and Sig(t) is a sigmoidal function. Further, since
the hydraulic resistance (Rh) of the occluding microchannel approximately scales as
Rh tð Þ ﬃ 1A tð Þ2 (ref. 43) and our device has parallel sections and every section will
not occlude equally at the same time, the hydraulic resistance of the whole device
would scale as Rh tð Þ ﬃ 1A tð Þk . This leads to the relationship,
Rh tð Þ
Rh 0ð Þ ¼ ð 11 Sig tð ÞÞ
k .
Further, based on the Hagen–Poiseuille law (Q¼DP/Rh) of laminar ﬂow, where Q
is ﬂow rate and DP is pressure drop across the device, we arrive at the following
general relation to predict the rise in pressure drop of an occluding device when
constant ﬂow is applied:
DPðtÞ
DPð0Þ ¼
1
1 Sig tð Þ
 k
ð2Þ
and
Sig tð Þ ¼ 1
1þ e
tTg
Ts Tg
  ; ð3Þ
where Tg and Ts are the characteristic parameters of the two-parameter sigmoid
function. Equations (2) and (3) lead to an exponential growth curve (reciprocal of
sigmoid) for pressure, of the form
DP tð Þ
DP 0ð Þ ¼ 1þ e
tTg
Ts Tg
  !k
; ð4Þ
where Tg and Ts represent time for the pressure to double and (1þ e) times its
initial value, respectively. The measured rise in pressure drop is not sensitive to
parameter k (Supplementary Fig. 6), and therefore, for simplicity and to reduce one
dimension from the equation (4), we assume k to be unity, which leads to the
approximation that the rise in pressure drop of an occluding microchannel follows
a two-parameter exponential growth curve described in equation (1).
Collagen coating of microdevices. To activate the surface, the device was ﬁrst
treated with oxygen plasma for 45 s at 100W followed by infusion of 2% solution
of (3-aminopropyl) trimethoxysilane (Sigma). The 2% (3-aminopropyl)
trimethoxysilane is prepared in 200 proof anhydrous ethanol (Sigma). Then, the
device was washed with 140 proof ethanol followed 200 proof ethanol (Koptec) and
then left to dry at 60 C for a few hours in a convection oven. Rat tail type I
collagen (Corning) was diluted in PBS and amine coupling reagent, N-(3-Dime-
thylaminopropyl)-N0-ethylcarbodiimide hydrochloride (20mgml 1; Sigma) in a
1:1 ratio to reach a ﬁnal concentration of 100mgml 1 and infused into the device.
The devices were incubated at 37 C for 3–4 h and then washed with 1% bovine
serum albumin solution followed by saline or PBS, before blood perfusion.
Blood samples. Blood samples were collected after informed, written consent as
per ethical guidelines of Institutional Review Board of Partners Healthcare,
Harvard Medical School and Beth Israel Deaconess Medical Center. Healthy
donors: blood was collected from non-smoking healthy volunteers in a standard
6ml no-additive blood vacutainer (BD) and 1000Uml 1 unfractionated heparin
was immediately added to a required concentration. Coagulation experiments were
initiated within B15min after the blood draw. For experiments where heparin
concentration was o0.25 IUml 1, blood was ﬁrst drawn in 3.2% 5ml sodium
citrate vacutainers (BD) or purchased (Research Blood Components, Cambridge,
MA). Patients: subjects who were taking aspirin and plavix (clopidogrel) were
selected from among patients seen in the cardiac catheterization laboratory at Beth
Israel Deaconess Medical Center, Boston, MA. Whole blood from patients with
HPS was drawn using standard phlebotomy techniques and stored in 4.5ml
citrated (3.2% sodium citrate) tubes at room temperature. Citrated blood was used
within 5 h of blood draw. The coagulation activity of these samples was restored by
adding 100 ml ml 1 of 100mM calcium chloride/75mM magnesium chloride
solution.
Anti-platelet drug. Abciximab (Reopro) was purchased from Boston Children’s
Hospital and diluted in saline to a desired concentration before adding to whole
blood.
Animal studies. All animal studies were approved by the Institutional Animal
Care and Use Committee at Boston Children’s Hospital and carried out in an
Association for Assessment and Accreditation of Laboratory Animal Care
accredited, United States Department of Agriculture (USDA) registered facility.
Female Yorkshire pigs (25–35 kg; 3–4 months old) were acclimatized for at least
72 h before experimentation. The animal was anaesthetised using standard pro-
cedures after which the bilateral femoral veins were percutaneously cannulated
with 5–8 French triple lumen catheters (Arrow International, Reading, PA). The
catheters were rinsed using multiple saline ﬂushes before use, and no catheter line
was used more than twice. A femoral artery was similarly catheterized for direct
measurement of mean arterial blood pressure. The microﬂuidic devices were
connected to the catheters via luer locks. The blood was pulled at a rate corre-
sponding to the shear rate gradient of 4,375 s 1mm 1. Endotoxemia: baseline
measurement of coagulation parameters were performed followed by infusion of
LPS endotoxin (E. Coli O26:B6 strain, Sigma) at a rate of 0.1–0.2 mg kg 1min 1
or 60–90min reaching an approximate total dose of 10 mg kg 1 (ref. 44). Fluid
therapy was maintained to support the blood pressure450mm Hg. At the end of
LPS infusion, devices were operated to measure microﬂuidic clotting time. Five to
ﬁfteen minutes later, in parallel to the devices, blood was drawn from one of the
catheter ports for aPTT/ACT/complete blood count (CBC)/Lab analysis. The
experiment was repeated (a new device was attached and old one discarded) every
hour for up to 6 h post-LPS infusion, allowing us to study and validate progression
of coagulopathy in this animal model. Heparin therapy: the microﬂuidic device was
connected to the catheter and then, a bolus dose of unfractionated heparin (0–
150 IU kg 1) was given to the animal intravenously. The device was operational
within 5–10min of the injection and ran until the analytical endpoint was reached
for each dose (pressure across the device rose ﬁve times the initial value or ﬂow was
reduced to nil inside the device or after the passage of 30min). In parallel, blood
samples were obtained for ACT/aPTT/CBC/lab analysis from one port of the
multi-lumen catheter at 15min after the heparin injection. After each injection of
heparin and the clotting analysis with devices, the animal was brought back to
baseline haemostasis conﬁrmed by monitoring aPTT/ACT values every hour. Once
haemostasis was restored,
another heparin dose was delivered to the same animal and a new experiment
was conducted with a new device attached. After recursively testing the clotting
times at various heparin doses in this way, at the end of the study, the animal was
euthanized under anaesthesia with injection of Fatal Plus.
Plasma biomarkers. Factor Xa: heparin was determined in blood platelet poor
plasma using a Factor Xa chromogenic kit (Chromogenix Antithrombin,
Diapharma Group, West Chester, Ohio)45. TAT complex: TAT using a sandwich
enzyme-linked immunosorbent assay (ELISA) assay were measured in plasma
using manufacturer’s instructions (Enzygnost TAT Micro Kit, Siemens
Healthcare). Fibrinogen was measured with ELISA assay using manufacturer’s
instructions (Fibrinogen porcine ELISA kit, ALPCO Immunoassays, Salem, NH).
Clotting time laboratory assays. CBC was performed in duplicate in 1ml EDTA
blood vacutainers (VetScan HM5, Abaxis, Union City, CA). aPTT was performed
in duplicate cartridges using citrated blood (VetScan VSpro, Abaxis, Union City,
CA). ACT was performed in duplicate using ACT tubes provided by the
manufacturer (Hemochron, Accriva Diagnostics). EDTA and citrate vacutainers
were manufactured by Becton Dickinson.
Scanning electron microscopy. The PDMS to PDMS bonded devices were peeled
off manually after thrombus formation. The post-stenosed region of the device was
cut in an B1 1 cm size and ﬁxed with 2.5 % glutaraldehyde in 0.1M sodium
cacodylate buffer (Electron Microscopy Sciences, Hatﬁeld PA) for 1 h, 1 % osmium
tetroxide in 0.1M sodium cacodylate (Electron Microscopy Sciences, Hatﬁeld PA)
for 1 h, dehydrated in ascending grades of ethanol, and chemically dried with
hexamethydisilazane (Electron Microscopy Sciences, Hatﬁeld PA). Samples were
sputter coated with 5 nm gold and imaged on a Zeiss Supra55VP microscope.
Statistical analysis. In vitro assay sample size was predetermined with three
separate healthy donors, nine subjects taking anti-platelet medication and two
patients with a rare HPS bleeding deﬁciency to account for biological variability.
For ex vivo studies, a sample size of three pigs was used to account for biological
variability. Blood samples were excluded only if they were 46 h old before the
study was conducted, and microﬂuidic devices were excluded due to fabrication
abnormalities, such as leakage. The goodness of ﬁt was quantiﬁed by the sum of
squares, from the best-ﬁt curve determined by nonlinear regression (R2) or linear
regression (r2). Data analysis, curve ﬁtting and goodness-of-ﬁt analysis were
performed using Graphpad Prism V6.
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